Standards for subgroup analyses are needed? - We couldn't agree more

Journal of Clinical Epidemiology

Volumn 64, Issue 4, 2011, Pages 451-

  Hasford, J ^a   Bramlage, P ^b   Koch, G ^c   Lehmacher, W ^d   Einhaupl K ^e   Rothwell, P M ^f  

^a UNIVERSITY OF MUNICH   (Germany)

^b Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^c IL   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTENTION TO TREAT ANALYSIS; LETTER; PERFORMANCE; PRIORITY JOURNAL; STANDARDIZATION;

DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN;

EID: 79951946020     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.10.001     Document Type: Letter

References (8)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
2. Hasford J, Lehmacher W. Benefit assessment in Germany. N Engl J Med 2010;362:e11; author reply e11.
3. Hasford J, Bramlage P, Koch G, Lehmacher W, Einhaupl K, Rothwell PM. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. J Clin Epidemiol 2010;63:1298-304.
4. NICE. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. London: NICE; 2005. Available at http://www.nice.org. uk/nicemedia/pdf/TA090guidance.pdf. Accessed October 4, 2010.
5. IQWiG. Final report plan for the evaluation: "clopidogrel versus acetyl salicylic acid in the secondary prevention of vascular events". Cologne: IQWiG; 2006. Available at http://www.iqwig.de/download/A04-01A- Abschlussbericht-Clopidogrel-versus-ASS-in-der-Sekun daerprophylaxe.pdf. Accessed October 4, 2010.
6. Bender R, Koch A, Skipka G, Kaiser T, Lange S. No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses. J Clin Epidemiol 2011;64:451-2.
7. Jackson D. The power of the standard test for the presence of heterogeneity in meta-analysis. Stat Med 2006;25:2688-99. (Pubitemid 44082455)
8. IQWiG. Allgemeine Methoden Version 3.0 vom 27.05.2008. Köln: IQWiG; 2008. Available at http://www.iqwig.de/download/IQWiG--Methoden-Version-3-0.pdf. Accessed October 4, 2010.